Permeon Biologics

Permeon Biologics was a biopharmaceutical company (founded 2011, ceased operations 2015) that developed intracellular biologics to target previously undruggable proteins by remodeling protein surfaces to enable cell penetration without losing structure or activity, using a platform licensed from Harvard University.